FDG PET in Movement Disorders and Parkinsonian Syndromes

Area of Science:

• Neurology
• Nuclear Medicine
• Neuroimaging

Background:

• Parkinsonian syndromes present diagnostic challenges due to overlapping clinical features.
• Accurate differential diagnosis is crucial for appropriate patient management and treatment.
• Existing imaging modalities have limitations in distinguishing between various parkinsonian disorders.

Purpose of the Study:

• To evaluate the utility of Fluorodeoxyglucose Positron Emission Tomography (FDG PET) in the differential diagnosis of parkinsonian syndromes.
• To compare the diagnostic performance of FDG PET with dopamine transporter imaging.
• To assess the impact of FDG PET on diagnostic confidence, particularly in early or atypical presentations.

Main Methods:

• Utilized FDG PET to identify regional and network-level metabolic signatures specific to different parkinsonian syndromes.
• Compared FDG PET findings with those from dopamine transporter imaging.
• Integrated FDG PET results with expert clinical assessment and multimodal imaging.

Main Results:

• FDG PET revealed distinct metabolic patterns differentiating various parkinsonian syndromes.
• FDG PET demonstrated superior performance over dopamine transporter imaging in distinguishing Parkinson disease from progressive supranuclear palsy, corticobasal degeneration/syndrome, multiple system atrophy, and Lewy body dementias.
• Combined use of FDG PET, clinical assessment, and multimodal imaging significantly enhanced diagnostic confidence.

Conclusions:

• FDG PET is a valuable tool for the differential diagnosis of parkinsonian syndromes, offering disease-specific metabolic insights.
• FDG PET provides better diagnostic discrimination than dopamine transporter imaging for several key parkinsonian disorders.
• Integrating FDG PET into multimodal diagnostic approaches substantially improves confidence, especially in challenging early or atypical cases.